Entera Bio Ltd. (ENTX): Price to Earnings Adjusted for Growth Rate
The P/E ratio relative to the company's growth rate is provided by the GURU.Markets service, with the value holding at 0.00. Entera Bio Ltd. (ENTX) is integrating ESG standards into its production, optimizing waste disposal and bioethics. The firm has developed a unique platform for the oral administration of hormones for osteoporosis. Current quotes price in the success of tests, while future growth depends on new partnerships.
Metric breakdowns and analytics for Entera Bio Ltd. (ENTX)
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- shareholders' equity book value data:
- business debt structure and liquidity details:
Debt to Capital Entera Bio Ltd.|ENTX - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital enterabio.com|ENTX - Company Aggregate Debts|Debts to Book Value Entera Bio Corp|ENTX - Company Long-Term Debt|Company Short-Term Indebtedness Entera Bio|Intermediate Liquidity Ratio enterabio.com
- earnings and market ratios statistics:
ENTX - Net Profit|Expected Net Profit Entera Bio Ltd.|ENTX - Price to Earnings Ratio|Future Price to Earnings Multiple enterabio.com|ENTX - PEG Multiple|EV/EBITDA Multiple Entera Bio Corp|ENTX - Operating profit before deduction of amortization|Earnings per share for the trailing year Entera Bio|ENTX - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months enterabio.com|ENTX - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Entera Bio Ltd.
General company analysis:ENTX - Entera Bio Ltd
The indicator is calculated by dividing the P/E ratio by the annual earnings growth rate. This metric determines the fair value of an asset by adjusting the market valuation for business expansion dynamics. For Entera Bio Ltd. (ENTX), such calculations are critical, as military risks in Israel may artificially depress the company's valuation. By analyzing the P/E to EPS growth ratio, an investor can identify undervalued "rockets." Values below one signal growth potential.
Competitors of Entera Bio Ltd.
HLN (Haleon PLC) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Kenvue Corp KVUE|Verona Pharma Inc. (VRNA) - Price to Earnings Adjusted for Growth Rate|MENS: Price/Earnings to Growth Multiple|ligand.com - Company Value to Earnings Growth Ratio|AMRX: PEG Multiple|Perrigo Company PLC - Growth-Adjusted Payback Ratio|ALVO (Alvotech Corp) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Liquidia Inc. LQDA|Price/Earnings to Growth Ratio Galapagos NV (GLPG)|ANIP (anipharmaceuticals.com) - Growth-Adjusted Payback Ratio|PEG Multiple MNKD (MannKind)|Amphastar Pharmaceuticals Inc (AMPH) - Price to Earnings Adjusted for Growth Rate|PCRX - Price/Earnings to Growth Ratio|SPRY (ARS Corp) - Growth-Adjusted P/E Ratio|TBPH (Theravance Biopharma) - Price/Earnings to Growth Multiple|AQST: Company Value to Earnings Growth Ratio|SCPH (scPharmaceuticals, Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Tectonic TECX|Price/Earnings to Growth Ratio Tonix Pharmaceuticals Inc. (TNXP)|SXTC (sxtchina.com) - Growth-Adjusted Payback Ratio|PEG Multiple EPRX (Eupraxia Pharmaceuticals Inc.)|PEG Multiple bioharvest.com BHST|EXOZ: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio ORMP (Oramed Pharmaceuticals)|HYFT: PEG Multiple|ABVC (ABVC BioPharma, Inc) - Price/Earnings to Growth Ratio|CPIX (Cumberland Pharmaceuticals) - PEG Multiple|quantumbiopharma.com (QNTM) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio FibroGen (FGEN)|TELO - Price to Earnings Adjusted for Growth Rate|Rani Therapeutics Holdings, Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio SNYR|RLYB - Price/Earnings to Growth Ratio|LEXX: Price/Earnings to Growth Ratio|PULM (Pulmatrix) - Price/Earnings to Growth Multiple|PTHL: Company Value to Earnings Growth Ratio|APM (Aptorum Group Ltd) - PEG Multiple|Growth-Adjusted P/E Ratio LYRA (Lyra Therapeutics Inc)|Price/Earnings to Growth Multiple IBO (Impact BioMedical Inc)|Growth-Adjusted Market Cap to Net Income tnfpharma.com|PEG Multiple YCBD (cbdMD)|PainReform Ltd (PRFX) - Price to Earnings Adjusted for Growth Rate|CYTO - Price/Earnings to Growth Ratio|LIPO (Lipella Pharma) - Growth-Adjusted P/E Ratio|OPTN (OptiNose, Inc.) - Price/Earnings to Growth Multiple|PIRS: Company Value to Earnings Growth Ratio|Price/Earnings to Growth Multiple PROC|Growth-Adjusted P/E Ratio PTPI (Petros Pharmaceuticals Inc)|Price/Earnings to Growth Ratio Qilian International Holding Group Limited (QLI)|SLRN: Market Cap to Earnings and Growth Ratio|PEG Multiple TFFP (TFF Pharmaceuticals)
